All In Biotech

Drug Trial Radar · NCT02999828

The Phase IVa of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17)

The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17)

Last checked: Nov 20, 2026Latest source record: Jan 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

20,770

Actual

Start

Sep 2016

Primary completion

Feb 2019

Study completion Feb 2019

Sponsor

Lead sponsor
Chinese Academy of Medical SciencesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Beijing Chaoyang District Centre for Disease Control and Prevention; Neimenggu Province Centre for Disease Control and Prevention
First posted
Dec 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 6 months, up to 71 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Enterovirus 71 (EV71), a major pathogen causing hand-foot-and-mouth disease (HFMD) worldwide, is a member of the Human Enterovirus species A, family Picornaviridae. Its infection occasionally leads to severe diseases and death, with central nervous system (CNS) damage. Recently, except of inactivated vaccine, several EV71 vaccine candidates have been evaluated in animals but no final results of clinical trials, such as attenuated vaccine, subunit vaccine. A formalin-inactivated EV71 vaccine (Human Diploid cell, KMB-17 Cell) has been finished phase I, II and III clinical trials and licensed by SFDA in China at Dec. 3, 2015. Based on the results of clinical trials, the protective efficacy of inactivated EV71 vaccine is 97% against HFMD caused by EV71. The phase IV clinical trial has been carried out from July 2016. The purpose of phase IV is to evaluated the safety and efficacy of the inactive EV71 vaccine in large scale population of Chinese children (from 6 to 71 months old).

Conditions

  • Safety of Inactivated EV71 Vaccine
  • Immunization of Inactivated EV71 Vaccine

Interventions

  • inactivated EV71 vaccine (KMB-17)Biological

    3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment adverse eventsTime frame: Up to 24 months after finishing 2 doses immunization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chaoyang of Provincial Center for Diseases Control and Prevention in Beijing

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.